RU2017116682A - Метадихол® - жидкие и гелевые нанолекарственные препараты - Google Patents
Метадихол® - жидкие и гелевые нанолекарственные препараты Download PDFInfo
- Publication number
- RU2017116682A RU2017116682A RU2017116682A RU2017116682A RU2017116682A RU 2017116682 A RU2017116682 A RU 2017116682A RU 2017116682 A RU2017116682 A RU 2017116682A RU 2017116682 A RU2017116682 A RU 2017116682A RU 2017116682 A RU2017116682 A RU 2017116682A
- Authority
- RU
- Russia
- Prior art keywords
- subject
- disease
- level
- lowering
- specified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Nanotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Composite Materials (AREA)
- Emergency Medicine (AREA)
- General Physics & Mathematics (AREA)
- Materials Engineering (AREA)
Claims (7)
1. Способ лечения заболевания, связанного с активностью рецептора VDR, путем улучшения физиологического или метаболического параметра у субъекта, при этом указанный способ предусматривает введение указанному субъекту терапевтически эффективного количества фармацевтического состава, содержащего наночастицы поликосанола, причем указанный параметр представляет собой элемент, выбранный из повышения уровней сывороточного белка апоA-1 у указанного субъекта, снижения липопротеин (a) (ЛП(а)) у указанного субъекта, повышения уровня гемоглобина у указанного субъекта, повышения количества тромбоцитов у указанного субъекта, снижения уровня мочевой кислоты у указанного субъекта, регулирования уровня рСКФ у указанного субъекта, регулирования элемента, выбранного из абсолютного содержания нейтрофилов, абсолютного содержания моноцитов и уровня лейкоцитов у указанного субъекта; снижения повышенных отношений АСТ:AЛT у указанного субъекта, снижения уровня ферритина у указанного субъекта, снижения уровня билирубина у указанного субъекта, регулирования уровня гормона щитовидной железы ТТГ у указанного субъекта и снижения уровня элемента, выбранного из уровней ПТГ, кальция, креатинина, щелочной фосфатазы, АМК и уровней фосфора в сыворотке крови, у субъекта с регулированием тем самым указанного параметра у указанного субъекта.
2. Способ по п. 1, где указанное заболевание представляет собой заболевание почек.
3. Способ по п. 1, где указанное заболевание представляет собой инфекцию МРЗС.
4. Способ по п. 1, где указанное заболевание представляет собой МДС.
5. Способ по п. 1, где указанное заболевание представляет собой гематологическое заболевание.
6. Способ по п. 1, где указанное заболевание представляет собой рак предстательной железы.
7. Способ по п. 1, где субъектом является человек.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361794490P | 2013-03-15 | 2013-03-15 | |
| US61/794,490 | 2013-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015143270A Division RU2631600C2 (ru) | 2013-03-15 | 2014-03-11 | Метадихол® - жидкие и гелевые нанолекарственные препараты |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017116682A true RU2017116682A (ru) | 2018-10-23 |
| RU2017116682A3 RU2017116682A3 (ru) | 2020-06-03 |
| RU2736752C2 RU2736752C2 (ru) | 2020-11-19 |
Family
ID=51530033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015143270A RU2631600C2 (ru) | 2013-03-15 | 2014-03-11 | Метадихол® - жидкие и гелевые нанолекарственные препараты |
| RU2017116682A RU2736752C2 (ru) | 2013-03-15 | 2014-03-11 | Метадихол - жидкие и гелевые нанолекарственные препараты |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015143270A RU2631600C2 (ru) | 2013-03-15 | 2014-03-11 | Метадихол® - жидкие и гелевые нанолекарственные препараты |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9006292B2 (ru) |
| EP (1) | EP2968209B1 (ru) |
| JP (2) | JP5996146B2 (ru) |
| KR (1) | KR101700949B1 (ru) |
| CN (1) | CN105188687B (ru) |
| AU (1) | AU2014235779B2 (ru) |
| BR (1) | BR112015011379B1 (ru) |
| CA (1) | CA2894370C (ru) |
| DK (1) | DK2968209T3 (ru) |
| HK (1) | HK1212247A1 (ru) |
| MX (1) | MX359686B (ru) |
| RU (2) | RU2631600C2 (ru) |
| SG (1) | SG11201506430XA (ru) |
| WO (1) | WO2014150609A1 (ru) |
| ZA (1) | ZA201505436B (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11554087B2 (en) | 2020-11-05 | 2023-01-17 | The Gillette Company Llc | Shaving aid comprising an antioxidant |
| WO2024105417A1 (en) * | 2022-11-18 | 2024-05-23 | Phytoceutical Limited | Biofilm treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4670471A (en) * | 1981-11-03 | 1987-06-02 | Clark Lealand L | Treatment for inflammatory skin disease |
| US20090191288A1 (en) | 1996-02-12 | 2009-07-30 | Squires Meryl J | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases |
| US20030198616A1 (en) * | 2002-04-23 | 2003-10-23 | Combe Incorporated | Moisturizing skin gel and method |
| CA2488498A1 (en) * | 2002-06-10 | 2003-12-18 | Elan Pharma International Limited | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| ITMI20031313A1 (it) * | 2003-06-27 | 2004-12-28 | Indena Spa | Associazioni di agenti vasoprotettori e formulazioni che li contengono. |
| US7217546B1 (en) * | 2003-07-01 | 2007-05-15 | Sami Labs Ltd | Commercially viable process for high purity of fatty alcohol C24 to C36 and its cosmetic application for skin hair and nails |
| US20050074443A1 (en) * | 2003-10-03 | 2005-04-07 | Treadwell Benjamin V. | Methods of attenuating autoimmune disease and compositions useful therefor |
| WO2008070602A2 (en) * | 2006-12-04 | 2008-06-12 | Smithkline Beecham Corporation | Topical pharmaceutical composition |
| AU2010216337B2 (en) * | 2009-02-23 | 2014-07-10 | NanoRx, Inc. | Policosanol nanoparticles |
| US10029013B2 (en) * | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| US9034383B2 (en) * | 2010-08-23 | 2015-05-19 | NanoRx, Inc. | Policosanol nanoparticles |
| US20130045179A1 (en) | 2011-08-15 | 2013-02-21 | Mihai Ciustea | Combination therapy and methods for treatment and prevention of hyperproliferative diseases |
-
2014
- 2014-03-11 CN CN201480016205.7A patent/CN105188687B/zh active Active
- 2014-03-11 KR KR1020157020035A patent/KR101700949B1/ko active IP Right Grant
- 2014-03-11 JP JP2016501340A patent/JP5996146B2/ja active Active
- 2014-03-11 RU RU2015143270A patent/RU2631600C2/ru active
- 2014-03-11 EP EP14770019.9A patent/EP2968209B1/en active Active
- 2014-03-11 SG SG11201506430XA patent/SG11201506430XA/en unknown
- 2014-03-11 CA CA2894370A patent/CA2894370C/en active Active
- 2014-03-11 RU RU2017116682A patent/RU2736752C2/ru active
- 2014-03-11 US US14/205,243 patent/US9006292B2/en active Active
- 2014-03-11 AU AU2014235779A patent/AU2014235779B2/en active Active
- 2014-03-11 DK DK14770019.9T patent/DK2968209T3/da active
- 2014-03-11 MX MX2015008676A patent/MX359686B/es active IP Right Grant
- 2014-03-11 WO PCT/US2014/023777 patent/WO2014150609A1/en active Application Filing
- 2014-03-11 BR BR112015011379-6A patent/BR112015011379B1/pt active IP Right Grant
-
2015
- 2015-07-28 ZA ZA2015/05436A patent/ZA201505436B/en unknown
-
2016
- 2016-01-13 HK HK16100350.6A patent/HK1212247A1/xx unknown
- 2016-07-12 JP JP2016137526A patent/JP6346918B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016512827A (ja) | 2016-05-09 |
| RU2736752C2 (ru) | 2020-11-19 |
| AU2014235779A1 (en) | 2015-09-03 |
| EP2968209A1 (en) | 2016-01-20 |
| BR112015011379A2 (ru) | 2017-08-22 |
| CN105188687B (zh) | 2018-05-01 |
| CN105188687A (zh) | 2015-12-23 |
| JP6346918B2 (ja) | 2018-06-20 |
| KR20150127575A (ko) | 2015-11-17 |
| HK1212247A1 (en) | 2016-06-10 |
| DK2968209T3 (da) | 2021-01-04 |
| RU2017116682A3 (ru) | 2020-06-03 |
| JP5996146B2 (ja) | 2016-09-21 |
| SG11201506430XA (en) | 2015-09-29 |
| BR112015011379B1 (pt) | 2022-10-11 |
| EP2968209B1 (en) | 2020-12-16 |
| ZA201505436B (en) | 2016-07-27 |
| WO2014150609A1 (en) | 2014-09-25 |
| MX359686B (es) | 2018-10-05 |
| CA2894370C (en) | 2016-01-12 |
| US9006292B2 (en) | 2015-04-14 |
| CA2894370A1 (en) | 2014-09-25 |
| KR101700949B1 (ko) | 2017-01-31 |
| JP2017008057A (ja) | 2017-01-12 |
| RU2015143270A (ru) | 2017-04-27 |
| MX2015008676A (es) | 2016-04-25 |
| EP2968209A4 (en) | 2016-11-02 |
| AU2014235779B2 (en) | 2015-11-26 |
| US20140275285A1 (en) | 2014-09-18 |
| RU2631600C2 (ru) | 2017-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Joannes-Boyau et al. | High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial | |
| EA201070553A1 (ru) | Антитела к гепцидину и варианты их применения | |
| HRP20191771T1 (hr) | Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije | |
| Maduell et al. | Nocturnal, every-other-day, online haemodiafiltration: an effective therapeutic alternative | |
| EA201070730A1 (ru) | Гуманизированные антитела, специфичные к фактору фон виллебранда | |
| EA201500997A1 (ru) | Терапевтические применения эмпаглифлозина | |
| EA201170312A1 (ru) | Селективные антитела к гепцидину-25 и их применение | |
| RU2017116682A (ru) | Метадихол® - жидкие и гелевые нанолекарственные препараты | |
| WO2011089234A8 (en) | Aqueous solution comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease | |
| EA201290671A1 (ru) | Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р | |
| Bonomini et al. | Biocompatibility of surface-modified membranes for chronic hemodialysis therapy | |
| IN2014CN04615A (ru) | ||
| Pedreros-Rosales et al. | Unveiling the clinical benefits of high-volume hemodiafiltration: Optimizing the removal of medium-weight uremic toxins and beyond | |
| Belcaro et al. | Silver oxide ointment wound dressing in venous ulcerations: home, self-management. | |
| Lehner et al. | Repeated premature hemofilter clotting during regional citrate anticoagulation as indicator of heparin induced thrombocytopenia | |
| RU2018131914A (ru) | Перфузионная система | |
| Kim et al. | A Profile of Serum Mineral Parameters in Korean CKD Patients on Maintenance Hemodialysis | |
| Perondi et al. | Pancreatitis and Acute Kidney Injury (AKI): retrospective observation of 41 dogs with AKI managed by hemodialysis. | |
| Gadayev | INDICATORS OF BLOOD AND URINE OF CATS PATIENTS WITH VESICAL CALCIFICATION | |
| Ibragimov et al. | CURRENT ISSUES OF HEMODIALYSIS AID IN THE RUSSIAN FEDERATION | |
| Keryakos et al. | MO578 OSTEOCALCIN AND VASCULAR CALCIFICATION IN HEMODIALYSIS PATIENTS: AN OBSERVATIONAL COHORT STUDY | |
| Wintz | Nausea, diarrhoea and paraesthesia: case report | |
| González | Results of the explicit health guaranties program to correct anemia of end stage renal disease patients in dialysis | |
| Szymonowicz | The influence of lysozyme dimmer on chosen parameters of blood in healthy rabbits | |
| Vishnevskii et al. | A pilot study of intradialytic epicutaneous bilateral electromyostimulation of lower extremities |